European Union regulator to unveil Astrazeneca vaccine assessment

The European Medicines Agency (EMA) is due to provide an assessment on Thursday of the safety of Astrazeneca's vaccine against Covid-19

AstraZeneca
Photo: Reuters
IANS Brussels
2 min read Last Updated : Mar 18 2021 | 2:46 PM IST

The European Medicines Agency (EMA) is due to provide an assessment on Thursday of the safety of Astrazeneca's vaccine against Covid-19 after several countries temporarily suspended use of the jab over fears about side effects.

The EMA's safety committee has been making a detailed evaluation of a small number of cases concerning blood clots occurring in recipients of the vaccine, reports dpa news agency.

The Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is to issue any necessary recommendations for further action after its meeting on Thursday.

The European nations that has halted the usage of the vaccine are France Germany, Italy, Spain, Slovenia, Cyprus, Portugal,Austria, Bulgaria, Denmark, Romania, Estonia, Lithuania, Luxembourg, Latvia, the Netherlands, as well as non-EU countries of Norway and Iceland.

Many said they were waiting for guidance from the EMA.

The EMA said it was looking at available data related to all thromboembolic events reported after vaccination, including additional data provided by national health agencies.

"Rapid and thorough analysis of the available data and clinical circumstances surrounding specific cases is continuing, to determine whether the vaccine might have contributed or if events are likely to have been due to other causes," the EMA said.

Both the EMA and the World Health Organization (WHO) recommended continuing inoculation with AstraZeneca's vaccine until further notice, noting its benefits outweighed the risks of Covid-19.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusEuropean UnionCoronavirus VaccineCoronavirus Tests

First Published: Mar 18 2021 | 2:45 PM IST

Next Story